ASH 2022 | Investigating the efficacy of TP-3654 in patients with myelofibrosis: results from Phase I study
Firas El Chaer, MD, University of Virginia, Charlottesville, VA, outlines results from a Phase I/II study evaluating the safety and efficacy of TP-3654, a selective oral PIM1 kinase inhibitor, in patients with relapsed/refractory (R/R) myelofibrosis (MF; NCT04176198). Overall, the preliminary clinical data from mouse models showed encouraging signs of clinical activity in spleen volume reduction, and evidence of efficacy in patients, with symptom improvement and cytokine reduction. Moreover, TP-3654 was well tolerated, with nausea and diarrhea being the main side effects recorded. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
